The Wall Street Journal, August 28, 2014: NCHR explains to WSJ that the FDA Diversity Action Plans lacks incentives for companies to study their medical products in a diverse group of patients, including sex, age, and race/ethnicity. The FDA urges diversity but approves drugs and implants that have only been evaluated on mostly white patients under 65.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Surgery Studies Rarely Use Females
The Scientist, August 28, 2014: The Scientist article on lack of women in clinical trials quotes NCHR telling MedPage Today that FDA must increase incentives for companies to include more women, older patients, and people of color in clinical trials. The FDA urges diversity but approves drugs and implants that have not been evaluated on all the types of patients who will want to use the product.
Read More »AIDS Activist Takes Up a New Fight: Defending FDA
Associated Press, June 12, 2014. This article quotes Gregg Gonsalves’ testimony at the Senate briefing hosted by the National Center for Health Research on June 12, 2014.
Read More »Johnson & Johnson Praised for Taking Uterine Surgery Tools Off Market
The New York Times, July 31, 2014. Johnson & Johnson, which has come under withering criticism for its response to problems with some of its medical devices, won cautious praise from critics on Thursday for its decision to withdraw three products used in uterine surgery because of a risk of spreading cancerous tissue, only months after the safety issue became widely known.
Read More »Big Data Peeps at Your Medical Records to Find Drug Problems
NPR, July 21, 2014. No one likes it when a new drug in people’s medicine cabinets turns out to have problems — just remember the Vioxx debacle a decade ago, when the painkiller was removed from the market over concerns that it increased the risk of heart attack and stroke. To do a better job of spotting unforeseen risks and side effects, the Food and Drug Administration is trying something new — and there’s a decent chance that it involves your medical records.
Read More »